VivoSim Labs, INC. (VIVS) stock
Close on Nov 13, 2026Market cap $1.89MP/E –Yield –
VivoSim Labs, INC. saw revenue fall 3.6% to $135.00K over the twelve months to Sep 30, 2026. Free cash flow was -$10.29M. At the latest close the market valued the company at $1.89M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.89M
- P/E ratio
- –
- Price to sales
- 13.98
- Price to book
- 0.26
- Dividend yield
- –
- Free cash flow yield
- -544.90%
Fundamentals
- Revenue
- $135.00K
- Net income
- -$10.27M
- EPS, diluted
- -$3.50
- Free cash flow
- -$10.29M
- Book value per share
- $0.44
- Diluted shares
- 16M
Trading
- Previous close
- $0.14
- Open
- $0.14
- Day's range
- $0.13 – $0.14
- Volume
- 457,765
- Average volume (20 days)
- 1,253,117
- Beta (5 years)
- 1.49
- 52-week range
- $0.12 – $3.40
- RSI (14 days)
- 36.0
- Volatility (1 year)
- 123.6%
- Relative volume
- 0.10×
- WACC
- 12.6%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | VIVS | S&P 500 | Difference | VIVS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.0% | -3.0% | −24.0 pts | ||
| 3 months | -61.3% | -2.8% | −58.5 pts | ||
| Year to date | -93.0% | +11.5% | −104.5 pts | ||
| 1 year | -94.1% | +13.5% | −107.5 pts | ||
| 3 years | -99.3% | +77.7% | −177.0 pts | -80.5% | +21.1% |
| 5 years | -99.8% | +72.6% | −172.4 pts | -71.6% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.1 pts | -58.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2010 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases VivoSim Labs filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Update
- Update
About VivoSim Labs
Biological Products, (No Diagnostic Substances)
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that provides drug and drug candidate testing using three-dimensional human tissue models of the liver and intestine. The company offers liver and intestinal toxicology insights and predictive screening through its new approach methodologies models, which are designed to forecast adverse effects and intestinal tolerability across various phases of drug development. Its primary customers include pharmaceutical and biotechnology companies seeking to evaluate therapeutic candidates and elucidate drug mechanisms of action.
Company profile, executives and historyVivoSim Labs stock: common questions
What is VivoSim Labs's stock price?
VIVS closed at $0.13 on Nov 13, 2026, down 7.83% on the day. Over the past 52 weeks it traded between $0.12 and $3.40.
What is VivoSim Labs's market cap?
VivoSim Labs was worth $1.89M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is VIVS's P/E ratio?
VivoSim Labs lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.50), so it has no meaningful P/E ratio.
How much revenue does VivoSim Labs make?
VivoSim Labs reported revenue of $135.00K for the twelve months to Sep 30, 2026, down 3.6% from a year earlier.
Does VivoSim Labs pay a dividend?
No. VivoSim Labs has not paid a cash dividend over the last twelve months.
How has VIVS stock performed over the past year?
Including dividends, VIVS returned -94.1% over the past year, against +13.5% for the S&P 500.
How many VIVS shares are sold short?
1M shares were sold short at the latest FINRA report, 7.95% of the float, or 1.0 days of average trading volume.
Who are VivoSim Labs's competitors?
Companies most similar to VivoSim Labs by business, industry and size include ATYR, ZIVO, ENTX, PALI, ABPO.
See a number that looks wrong?